{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:55:17Z","timestamp":1781636117455,"version":"3.54.5"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"vor","delay-in-days":30,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Gastroenteropancreatic neuroendocrine tumours (GEP-NETs) are commonly treated with radio-ligand therapy (RLT) but reliable biomarkers for predicting early disease progression are lacking. In this exploratory study we investigated whether microRNA (miRNA) expression in archival samples is associated with early response to RLT and with tumour origin and grading. Forty-eight formalin-fixed, paraffin-embedded samples from G1\u2013G2 GEP-NETs patients treated with RLT (\n                    <jats:sup>177<\/jats:sup>\n                    Lu-Oxodotreotide (Lutathera\n                    <jats:sup>\u00ae<\/jats:sup>\n                    ) were analyzed. Two CT or MRI scans per patient, performed within three months before and after RLT, were used to assess early progression (PD) according to RECIST v1.1. Thirteen miRNAs previously implicated in NET biology were quantified by qRT-PCR. Multiple logistic regression evaluated associations between miRNA expression and early progression, as well as relationships with tumour origin and grade. We observed trends suggesting that lower expression of miR-21-5p (OR\u2009=\u20090.51, 90% CI: 0.26\u20131.00) and miR-196a (OR\u2009=\u20090.78, 90% CI: 0.59\u20131.02), and higher expression of miR\u201130a-5p (OR\u2009=\u20092.62, 90% CI: 0.1.14\u20136.05) may be associated with a reduced likelihood of early progression. Lower miR-196a and higher miR\u201130a-5p expression was also more frequent in pancreatic tumours and lower miR-196a expression is associated to G1 lesions. These findings indicate that miRNA profiling in GEP-NETs archival samples is feasible and support the potential role of miR-21-5p, miR-196a, and miR\u201130a-5p as exploratory biomarkers for early progression afterRLT. Further validation in independent cohorts is required to confirm these preliminary observations.\n                  <\/jats:p>","DOI":"10.1038\/s41598-026-40046-z","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T09:25:33Z","timestamp":1771320333000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Investigation of MicroRNAs as predictors of radioligand therapy response in gastroenteropancreatic neuroendocrine tumours"],"prefix":"10.1038","volume":"16","author":[{"given":"Federica","family":"Scalorbi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico Matteo","family":"Garanzini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Marzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Gariboldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppina","family":"Calareso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Baccini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Sabella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Pusceddu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonso","family":"Marchian\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Roz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Milione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Maccauro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,17]]},"reference":[{"key":"40046_CR1","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/0092-8674(93)90529-Y","volume":"75","author":"RC Lee","year":"1993","unstructured":"Lee, R. C., Feinbaum, R. L. & Ambros, V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 75, 843\u2013854 (1993).","journal-title":"Cell"},{"key":"40046_CR2","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s10555-009-9188-5","volume":"28","author":"SK Shenouda","year":"2009","unstructured":"Shenouda, S. K. & Alahari, S. K. MicroRNA function in cancer: oncogene or a tumor suppressor? Cancer Metastasis Rev. 28, 369\u2013378 (2009).","journal-title":"Cancer Metastasis Rev."},{"key":"40046_CR3","doi-asserted-by":"publisher","first-page":"708765","DOI":"10.3389\/fonc.2021.708765","volume":"11","author":"K Otmani","year":"2021","unstructured":"Otmani, K. & Lewalle, P. Tumor suppressor MiRNA in cancer cells and the tumor microenvironment: mechanism of deregulation and clinical implications. Front. Oncol. 11, 708765 (2021).","journal-title":"Front. Oncol."},{"key":"40046_CR4","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1002\/cac2.12138","volume":"41","author":"G Pan","year":"2021","unstructured":"Pan, G., Liu, Y., Shang, L., Zhou, F. & Yang, S. EMT-associated MicroRNAs and their roles in cancer stemness and drug resistance. Cancer Commun. 41, 199\u2013217 (2021).","journal-title":"Cancer Commun."},{"key":"40046_CR5","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13148-018-0587-8","volume":"11","author":"W Si","year":"2019","unstructured":"Si, W., Shen, J., Zheng, H. & Fan, W. The role and mechanisms of action of MicroRNAs in cancer drug resistance. Clin. Epigenet. 11, 25 (2019).","journal-title":"Clin. Epigenet"},{"key":"40046_CR6","doi-asserted-by":"publisher","first-page":"8259","DOI":"10.1158\/0008-5472.CAN-10-0604","volume":"70","author":"M Katakowski","year":"2010","unstructured":"Katakowski, M., Buller, B., Wang, X., Rogers, T. & Chopp, M. Functional MicroRNA is transferred between glioma cells. Cancer Res. 70, 8259\u20138263 (2010).","journal-title":"Cancer Res."},{"key":"40046_CR7","doi-asserted-by":"publisher","first-page":"6738","DOI":"10.1038\/s41467-021-27099-6","volume":"12","author":"P Carotenuto","year":"2021","unstructured":"Carotenuto, P. et al. Modulation of pancreatic cancer cell sensitivity to FOLFIRINOX through microRNA-mediated regulation of DNA damage. Nat. Commun. 12, 6738 (2021).","journal-title":"Nat. Commun."},{"key":"40046_CR8","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1002\/ijc.31539","volume":"143","author":"LMA De Strooper","year":"2018","unstructured":"De Strooper, L. M. A. et al. Cervical cancer risk in HPV-positive women after a negative FAM19A4\/mir124\u20102 methylation test: A post hoc analysis in the POBASCAM trial with 14 year follow\u2010up. Intl J. Cancer. 143, 1541\u20131548 (2018).","journal-title":"Intl J. Cancer"},{"key":"40046_CR9","doi-asserted-by":"crossref","unstructured":"Di Cosimo, S. et al. Early Modulation of Circulating MicroRNAs Levels in HER2-Positive Breast Cancer Patients Treated with Trastuzumab-Based Neoadjuvant Therapy. IJMS 21, 1386 (2020).","DOI":"10.3390\/ijms21041386"},{"key":"40046_CR10","doi-asserted-by":"publisher","first-page":"e0251676","DOI":"10.1371\/journal.pone.0251676","volume":"16","author":"Y Liu","year":"2021","unstructured":"Liu, Y., Geng, H., Liu, X., Cao, M. & Zhang, X. A meta-analysis of Circulating MicroRNAs in the diagnosis of papillary thyroid carcinoma. PLoS ONE. 16, e0251676 (2021).","journal-title":"PLoS ONE"},{"key":"40046_CR11","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1007\/s12020-017-1273-x","volume":"58","author":"E Leoncini","year":"2017","unstructured":"Leoncini, E. et al. Increased incidence trend of low-grade and high-grade neuroendocrine neoplasms. Endocrine 58, 368\u2013379 (2017).","journal-title":"Endocrine"},{"key":"40046_CR12","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","volume":"26","author":"JC Yao","year":"2008","unstructured":"Yao, J. C. et al. One hundred years after carcinoid: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the united States. JCO 26, 3063\u20133072 (2008).","journal-title":"JCO"},{"key":"40046_CR13","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1097\/CCO.0000000000000299","volume":"28","author":"M Cives","year":"2016","unstructured":"Cives, M., Soares, H. P. & Strosberg, J. Will clinical heterogeneity of neuroendocrine tumors impact their management in the future? Lessons from recent trials. Curr. Opin. Oncol. 28, 359\u2013366 (2016).","journal-title":"Curr. Opin. Oncol."},{"key":"40046_CR14","doi-asserted-by":"publisher","first-page":"e220290","DOI":"10.1001\/jamanetworkopen.2022.0290","volume":"5","author":"S Pusceddu","year":"2022","unstructured":"Pusceddu, S. et al. Association of upfront peptide receptor radionuclide therapy with Progression-Free survival among patients with enteropancreatic neuroendocrine tumors. JAMA Netw. Open. 5, e220290 (2022).","journal-title":"JAMA Netw. Open."},{"key":"40046_CR15","doi-asserted-by":"publisher","first-page":"19490","DOI":"10.1038\/s41598-021-99048-8","volume":"11","author":"F Scalorbi","year":"2021","unstructured":"Scalorbi, F. et al. Application of FLIC model to predict adverse events onset in neuroendocrine tumors treated with PRRT. Sci. Rep. 11, 19490 (2021).","journal-title":"Sci. Rep."},{"key":"40046_CR16","doi-asserted-by":"publisher","first-page":"491","DOI":"10.7150\/thno.51215","volume":"11","author":"D Feijtel","year":"2021","unstructured":"Feijtel, D. et al. Inter and intra-tumor somatostatin receptor 2 heterogeneity influences peptide receptor radionuclide therapy response. Theranostics 11, 491\u2013505 (2021).","journal-title":"Theranostics"},{"key":"40046_CR17","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1007\/s40618-020-01275-9","volume":"43","author":"E Guadagno","year":"2020","unstructured":"Guadagno, E., D\u2019Avella, E., Cappabianca, P. & Colao, A. Del Basso de Caro, M. Ki67 in endocrine neoplasms: to count or not to count, this is the question! A systematic review from the english Language literature. J. Endocrinol. Invest. 43, 1429\u20131445 (2020).","journal-title":"J. Endocrinol. Invest."},{"key":"40046_CR18","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s00259-024-06863-y","volume":"52","author":"M Maccauro","year":"2024","unstructured":"Maccauro, M. et al. The LUTADOSE trial: tumour dosimetry after the first administration predicts progression free survival in gastro-entero-pancreatic neuroendocrine tumours (GEP NETs) patients treated with [177Lu]Lu-DOTATATE. Eur. J. Nucl. Med. Mol. Imaging. 52, 291\u2013304 (2024).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"40046_CR19","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.ecl.2018.05.002","volume":"47","author":"IM Modlin","year":"2018","unstructured":"Modlin, I. M. et al. The netest. Endocrinol. Metab. Clin. North Am. 47, 485\u2013504 (2018).","journal-title":"Endocrinol. Metab. Clin. North Am."},{"key":"40046_CR20","doi-asserted-by":"publisher","first-page":"e435","DOI":"10.1016\/S1470-2045(15)00186-2","volume":"16","author":"K Oberg","year":"2015","unstructured":"Oberg, K. et al. Consensus on biomarkers for neuroendocrine tumour disease. Lancet Oncol. 16, e435\u2013e446 (2015).","journal-title":"Lancet Oncol."},{"key":"40046_CR21","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1038\/s41379-018-0010-1","volume":"31","author":"Y Arvidsson","year":"2018","unstructured":"Arvidsson, Y. et al. MiRNA profiling of small intestinal neuroendocrine tumors defines novel molecular subtypes and identifies miR-375 as a biomarker of patient survival. Mod. Pathol. 31, 1302\u20131317 (2018).","journal-title":"Mod. Pathol."},{"key":"40046_CR22","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s12022-017-9504-5","volume":"28","author":"R Mandal","year":"2017","unstructured":"Mandal, R., Hardin, H., Baus, R., Rehrauer, W. & Lloyd, R. V. Analysis of miR-96 and miR-133a expression in Gastrointestinal neuroendocrine neoplasms. Endocr. Pathol. 28, 345\u2013350 (2017).","journal-title":"Endocr. Pathol."},{"key":"40046_CR23","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1530\/ERC-18-0244","volume":"26","author":"N Panarelli","year":"2019","unstructured":"Panarelli, N. et al. Evaluating gastroenteropancreatic neuroendocrine tumors through MicroRNA sequencing. Endocr. Relat. Cancer. 26, 47\u201357 (2019).","journal-title":"Endocr. Relat. Cancer"},{"key":"40046_CR24","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s12876-020-01287-y","volume":"20","author":"C Vicentini","year":"2020","unstructured":"Vicentini, C. et al. Exosomal MiRNA signatures of pancreatic lesions. BMC Gastroenterol. 20, 137 (2020).","journal-title":"BMC Gastroenterol."},{"key":"40046_CR25","doi-asserted-by":"publisher","first-page":"28379","DOI":"10.18632\/oncotarget.25357","volume":"9","author":"N Zimmermann","year":"2018","unstructured":"Zimmermann, N. et al. MicroRNA analysis of gastroenteropancreatic neuroendocrine tumors and metastases. Oncotarget 9, 28379\u201328390 (2018).","journal-title":"Oncotarget"},{"key":"40046_CR26","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1530\/ERC-21-0052","volume":"28","author":"C Borga","year":"2021","unstructured":"Borga, C. et al. mTOR pathway and somatostatin receptors expression intratumor-heterogeneity in ileal NETs. Endocr. Relat. Cancer. 28, 449\u2013456 (2021).","journal-title":"Endocr. Relat. Cancer"},{"key":"40046_CR27","doi-asserted-by":"publisher","first-page":"54331","DOI":"10.18632\/oncotarget.16908","volume":"8","author":"M Bowden","year":"2017","unstructured":"Bowden, M. et al. Profiling of metastatic small intestine neuroendocrine tumors reveals characteristic MiRNAs detectable in plasma. Oncotarget 8, 54331\u201354344 (2017).","journal-title":"Oncotarget"},{"key":"40046_CR28","doi-asserted-by":"publisher","first-page":"647","DOI":"10.15403\/jgld-2866","volume":"29","author":"AM Curt","year":"2020","unstructured":"Curt, A. M., Popa Ilie, I. R., Cainap, C., Balacescu, O. & Ghervan, C. MicroRNAs and treatment with somatostatin analogs in Gastro- Entero-Pancreatic neuroendocrine neoplasms: challenges in personalized medicine. JGLD 29, 647\u2013659 (2020).","journal-title":"JGLD"},{"key":"40046_CR29","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1007\/s12022-019-9570-y","volume":"30","author":"P Gill","year":"2019","unstructured":"Gill, P. et al. MiRNA-3653 is a potential tissue biomarker for increased metastatic risk in pancreatic neuroendocrine tumours. Endocr. Pathol. 30, 128\u2013133 (2019).","journal-title":"Endocr. Pathol."},{"key":"40046_CR30","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.3390\/cancers12092488","volume":"12","author":"A K\u00f6vesdi","year":"2020","unstructured":"K\u00f6vesdi, A. et al. Circulating MiRNA increases the diagnostic accuracy of chromogranin A in metastatic pancreatic neuroendocrine tumors. Cancers 12, 2488 (2020).","journal-title":"Cancers"},{"key":"40046_CR31","doi-asserted-by":"publisher","first-page":"8569","DOI":"10.3390\/ijms22168569","volume":"22","author":"L Geisler","year":"2021","unstructured":"Geisler, L. et al. The role of MiRNA in the pathophysiology of neuroendocrine tumors. IJMS 22, 8569 (2021).","journal-title":"IJMS"},{"key":"40046_CR32","doi-asserted-by":"publisher","first-page":"8075","DOI":"10.1002\/jcp.27580","volume":"234","author":"A Bahreyni","year":"2019","unstructured":"Bahreyni, A. et al. Diagnostic, prognostic, and therapeutic potency of MicroRNA 21 in the pathogenesis of colon cancer, current status and prospective. J. Cell. Physiol. 234, 8075\u20138081 (2019).","journal-title":"J. Cell. Physiol."},{"key":"40046_CR33","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/j.1582-4934.2010.01219.x","volume":"15","author":"C Chen","year":"2011","unstructured":"Chen, C., Zhang, Y., Zhang, L., Weakley, S. M. & Yao, Q. MicroRNA-196: critical roles and clinical applications in development and cancer. J. Cell. Mol. Medi. 15, 14\u201323 (2011).","journal-title":"J. Cell. Mol. Medi"},{"key":"40046_CR34","doi-asserted-by":"publisher","first-page":"1136331","DOI":"10.3389\/fonc.2023.1136331","volume":"13","author":"M Bocchini","year":"2023","unstructured":"Bocchini, M. et al. Circulating hsa-miR-5096 predicts 18F-FDG PET\/CT positivity and modulates somatostatin receptor 2 expression: a novel miR-based assay for pancreatic neuroendocrine tumors. Front. Oncol. 13, 1136331 (2023).","journal-title":"Front. Oncol."},{"key":"40046_CR35","doi-asserted-by":"publisher","first-page":"4677","DOI":"10.1200\/JCO.2005.05.5194","volume":"24","author":"C Roldo","year":"2006","unstructured":"Roldo, C. et al. MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior. JCO 24, 4677\u20134684 (2006).","journal-title":"JCO"},{"key":"40046_CR36","doi-asserted-by":"publisher","first-page":"e2224","DOI":"10.1097\/MD.0000000000002224","volume":"94","author":"YS Lee","year":"2015","unstructured":"Lee, Y. S. et al. High expression of MicroRNA-196a indicates poor prognosis in resected pancreatic neuroendocrine tumor. Medicine 94, e2224 (2015).","journal-title":"Medicine"},{"key":"40046_CR37","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1093\/carcin\/bgs020","volume":"33","author":"A Baraniskin","year":"2012","unstructured":"Baraniskin, A. et al. MiR-30a-5p suppresses tumor growth in colon carcinoma by targeting DTL. Carcinogenesis 33, 732\u2013739 (2012).","journal-title":"Carcinogenesis"},{"key":"40046_CR38","doi-asserted-by":"publisher","first-page":"e2859","DOI":"10.1038\/cddis.2017.252","volume":"8","author":"Z Chen","year":"2017","unstructured":"Chen, Z. et al. The putative tumor suppressor microRNA-30a-5p modulates clear cell renal cell carcinoma aggressiveness through repression of ZEB2. Cell. Death Dis. 8, e2859\u2013e2859 (2017).","journal-title":"Cell. Death Dis."},{"key":"40046_CR39","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.3390\/ijms18081826","volume":"18","author":"YH Chung","year":"2017","unstructured":"Chung, Y. H. et al. MiR-30a-5p inhibits Epithelial-to-Mesenchymal transition and upregulates expression of tight junction protein Claudin-5 in human upper tract urothelial carcinoma cells. Int. J. Mol. Sci. 18, 1826 (2017).","journal-title":"Int. J. Mol. Sci."},{"key":"40046_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2018\/5167829","volume":"2018","author":"L Jiang","year":"2018","unstructured":"Jiang, L., Zhang, H. & Tang, J. MiR-30a: A novel biomarker and potential therapeutic target for cancer. J. Oncol. 2018, 1\u20139 (2018).","journal-title":"J. Oncol."},{"key":"40046_CR41","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1186\/s12885-016-2231-3","volume":"16","author":"O Peralta-Zaragoza","year":"2016","unstructured":"Peralta-Zaragoza, O. et al. Relevance of miR-21 in regulation of tumor suppressor gene PTEN in human cervical cancer cells. BMC Cancer. 16, 215 (2016).","journal-title":"BMC Cancer"},{"key":"40046_CR42","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1530\/EJE-18-0305","volume":"179","author":"VK Grolmusz","year":"2018","unstructured":"Grolmusz, V. K., K\u00f6vesdi, A., Borka, K., Igaz, P. & Pat\u00f3cs, A. Prognostic relevance of proliferation-related MiRNAs in pancreatic neuroendocrine neoplasms. Eur. J. Endocrinol. 179, 219\u2013228 (2018).","journal-title":"Eur. J. Endocrinol."},{"key":"40046_CR43","doi-asserted-by":"publisher","first-page":"626836","DOI":"10.3389\/fonc.2020.626836","volume":"10","author":"D Kalathil","year":"2020","unstructured":"Kalathil, D., John, S. & Nair, A. S. FOXM1 and cancer: faulty cellular signaling derails homeostasis. Front. Oncol. 10, 626836 (2020).","journal-title":"Front. Oncol."},{"key":"40046_CR44","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1016\/j.molcel.2009.09.006","volume":"35","author":"X Huang","year":"2009","unstructured":"Huang, X. et al. Hypoxia-Inducible mir-210 regulates normoxic gene expression involved in tumor initiation. Mol. Cell. 35, 856\u2013867 (2009).","journal-title":"Mol. Cell"},{"key":"40046_CR45","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.mce.2017.03.015","volume":"456","author":"CR Lima","year":"2017","unstructured":"Lima, C. R., Gomes, C. C. & Santos, M. F. Role of MicroRNAs in endocrine cancer metastasis. Mol. Cell. Endocrinol. 456, 62\u201375 (2017).","journal-title":"Mol. Cell. Endocrinol."},{"key":"40046_CR46","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1186\/1471-2164-14-589","volume":"14","author":"S Pizzini","year":"2013","unstructured":"Pizzini, S. et al. Impact of MicroRNAs on regulatory networks and pathways in human colorectal carcinogenesis and development of metastasis. BMC Genom. 14, 589 (2013).","journal-title":"BMC Genom."},{"key":"40046_CR47","doi-asserted-by":"publisher","first-page":"3600","DOI":"10.1158\/1078-0432.CCR-12-3092","volume":"19","author":"A Li","year":"2013","unstructured":"Li, A. et al. MicroRNA array analysis finds elevated serum miR-1290 accurately distinguishes patients with Low-Stage pancreatic cancer from healthy and disease controls. Clin. Cancer Res. 19, 3600\u20133610 (2013).","journal-title":"Clin. Cancer Res."},{"key":"40046_CR48","doi-asserted-by":"publisher","first-page":"114129","DOI":"10.1016\/j.ejca.2024.114129","volume":"208","author":"A Bongiovanni","year":"2024","unstructured":"Bongiovanni, A. et al. A randomized phase II trial of Captem or Folfiri as second-line therapy in neuroendocrine carcinomas. Eur. J. Cancer. 208, 114129 (2024).","journal-title":"Eur. J. Cancer"},{"key":"40046_CR49","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1159\/000475526","volume":"105","author":"RJ Hicks","year":"2017","unstructured":"Hicks, R. J. et al. ENETS consensus guidelines for the standards of care in neuroendocrine neoplasms: peptide receptor radionuclide therapy with radiolabelled somatostatin analogues. Neuroendocrinology 105, 295\u2013309 (2017).","journal-title":"Neuroendocrinology"},{"key":"40046_CR50","doi-asserted-by":"publisher","first-page":"101827","DOI":"10.1016\/j.beem.2023.101827","volume":"37","author":"M Ronot","year":"2023","unstructured":"Ronot, M. et al. Appropriate use of morphological imaging for assessing treatment response and disease progression of neuroendocrine tumors. Best Pract. Res. Clin. Endocrinol. Metab. 37, 101827 (2023).","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"40046_CR51","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s40644-020-00335-w","volume":"20","author":"DMV Huizing","year":"2020","unstructured":"Huizing, D. M. V. et al. Early response assessment and prediction of overall survival after peptide receptor radionuclide therapy. Cancer Imaging. 20, 57 (2020).","journal-title":"Cancer Imaging"},{"key":"40046_CR52","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s12885-017-3150-7","volume":"17","author":"Y Luo","year":"2017","unstructured":"Luo, Y. et al. Early evaluation of Sunitinib for the treatment of advanced gastroenteropancreatic neuroendocrine neoplasms via CT imaging: RECIST 1.1 or Choi criteria? BMC Cancer. 17, 154 (2017).","journal-title":"BMC Cancer"},{"key":"40046_CR53","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/s41416-019-0558-7","volume":"121","author":"MP Solis-Hernandez","year":"2019","unstructured":"Solis-Hernandez, M. P. et al. Evaluating radiological response in pancreatic neuroendocrine tumours treated with sunitinib: comparison of Choi versus RECIST criteria (CRIPNET_ GETNE1504 study). Br. J. Cancer. 121, 537\u2013544 (2019).","journal-title":"Br. J. Cancer"},{"key":"40046_CR54","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1007\/s00261-021-03393-1","volume":"47","author":"MJC Van Treijen","year":"2022","unstructured":"Van Treijen, M. J. C. et al. Defining disease status in gastroenteropancreatic neuroendocrine tumors: Choi-criteria or RECIST? Abdom. Radiol. 47, 1071\u20131081 (2022).","journal-title":"Abdom. Radiol."},{"key":"40046_CR55","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1159\/000090026","volume":"6","author":"M Rodallec","year":"2006","unstructured":"Rodallec, M. et al. Endocrine pancreatic tumours and helical CT: contrast enhancement is correlated with microvascular Density, histoprognostic factors and survival. Pancreatology 6, 77\u201385 (2006).","journal-title":"Pancreatology"},{"key":"40046_CR56","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1158\/1078-0432.CCR-13-2098","volume":"20","author":"C Fert\u00e9","year":"2014","unstructured":"Fert\u00e9, C. et al. Tumor growth rate is an early indicator of antitumor drug activity in phase I clinical trials. Clin. Cancer Res. 20, 246\u2013252 (2014).","journal-title":"Clin. Cancer Res."},{"key":"40046_CR57","doi-asserted-by":"publisher","first-page":"R105","DOI":"10.1530\/ERC-13-0365","volume":"21","author":"L De Mestier","year":"2014","unstructured":"De Mestier, L. et al. Evaluating digestive neuroendocrine tumor progression and therapeutic responses in the era of targeted therapies: state of the Art. Endocr. Relat. Cancer. 21, R105\u2013R120 (2014).","journal-title":"Endocr. Relat. Cancer"},{"key":"40046_CR58","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1159\/000510445","volume":"111","author":"C Dromain","year":"2021","unstructured":"Dromain, C. et al. Tumor growth rate to predict the outcome of patients with neuroendocrine tumors: performance and sources of variability. Neuroendocrinology 111, 831\u2013839 (2021).","journal-title":"Neuroendocrinology"},{"key":"40046_CR59","doi-asserted-by":"publisher","first-page":"e1082","DOI":"10.1634\/theoncologist.2018-0672","volume":"24","author":"A Lamarca","year":"2019","unstructured":"Lamarca, A. et al. Value of tumor growth rate (TGR) as an early biomarker predictor of patients\u2019 outcome in neuroendocrine tumors (NET)\u2014The GREPONET study. Oncologist 24, e1082\u2013e1090 (2019).","journal-title":"Oncologist"},{"key":"40046_CR60","doi-asserted-by":"publisher","first-page":"6692","DOI":"10.1158\/1078-0432.CCR-19-0963","volume":"25","author":"A Lamarca","year":"2019","unstructured":"Lamarca, A. et al. Tumor growth rate as a validated early radiological biomarker able to reflect Treatment-Induced changes in neuroendocrine tumors: the GREPONET-2 study. Clin. Cancer Res. 25, 6692\u20136699 (2019).","journal-title":"Clin. Cancer Res."},{"key":"40046_CR61","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1530\/EC-21-0027","volume":"10","author":"OJ Pettersson","year":"2021","unstructured":"Pettersson, O. J., Fr\u00f6ss-Baron, K., Crona, J. & Sundin, A. Tumor growth rate in pancreatic neuroendocrine tumor patients undergoing PRRT with 177Lu-DOTATATE. Endocr. Connections. 10, 422\u2013431 (2021).","journal-title":"Endocr. Connections"},{"key":"40046_CR62","doi-asserted-by":"publisher","first-page":"e13260","DOI":"10.1111\/jne.13260","volume":"35","author":"SJ Wang","year":"2023","unstructured":"Wang, S. J. et al. Baseline tumor growth rate highlights the heterogeneity of well differentiated gastroenteropancreatic neuroendocrine tumors and predicts for increases in Ki67 index over time. J. Neuroendocrinol. 35, e13260 (2023).","journal-title":"J. Neuroendocrinol."},{"key":"40046_CR63","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.3390\/medicina61101852","volume":"61","author":"R Modica","year":"2025","unstructured":"Modica, R. et al. Tumor growth rate in neuroendocrine neoplasms: an additional tool for treatment strategies? Medicina 61, 1852 (2025).","journal-title":"Medicina"},{"key":"40046_CR64","first-page":"988","volume":"76","author":"VP Collins","year":"1956","unstructured":"Collins, V. P. Observations on growth rates of human tumors. AJR 76, 988\u20131000 (1956).","journal-title":"AJR"},{"key":"40046_CR65","doi-asserted-by":"publisher","first-page":"15782","DOI":"10.1038\/s41598-024-66668-9","volume":"14","author":"F Scalorbi","year":"2024","unstructured":"Scalorbi, F. et al. Cylindrical TGR as early radiological predictor of RLT progression in gepnets: a proof of concept. Sci. Rep. 14, 15782 (2024).","journal-title":"Sci. Rep."},{"key":"40046_CR66","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s11307-014-0795-3","volume":"17","author":"C Kratochwil","year":"2015","unstructured":"Kratochwil, C. et al. SUV of [68Ga]DOTATOC-PET\/CT predicts response probability of PRRT in neuroendocrine tumors. Mol. Imaging Biol. 17, 313\u2013318 (2015).","journal-title":"Mol. Imaging Biol."},{"key":"40046_CR67","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using Real-Time quantitative PCR and the 2\u2009\u2013 \u2206\u2206CT method. Methods 25, 402\u2013408 (2001).","journal-title":"Methods"},{"key":"40046_CR68","doi-asserted-by":"publisher","unstructured":"Multiple Imputation for Nonresponse in Surveys. (John Wiley & Sons, Inc., Hoboken, NJ, USA, 1987). https:\/\/doi.org\/10.1002\/9780470316696","DOI":"10.1002\/9780470316696"},{"key":"40046_CR69","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s10654-016-0149-3","volume":"31","author":"S Greenland","year":"2016","unstructured":"Greenland, S. et al. Statistical tests, P values, confidence intervals, and power: a guide to misinterpretations. Eur. J. Epidemiol. 31, 337\u2013350 (2016).","journal-title":"Eur. J. Epidemiol."},{"key":"40046_CR70","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/00031305.2019.1583913","volume":"73","author":"RL Wasserstein","year":"2019","unstructured":"Wasserstein, R. L., Schirm, A. L. & Lazar, N. A. Moving to a world beyond p <\u20090.05. Am. Stat. 73, 1\u201319 (2019).","journal-title":"Am. Stat."},{"key":"40046_CR71","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/jeq2.20452","volume":"52","author":"J Mandal","year":"2023","unstructured":"Mandal, J. et al. Determination of bioavailable arsenic threshold and validation of modeled permissible total arsenic in paddy soil using machine learning. J. Environ. Qual. 52, 315\u2013327 (2023).","journal-title":"J. Environ. Qual."},{"key":"40046_CR72","doi-asserted-by":"publisher","first-page":"2316","DOI":"10.2741\/2234","volume":"12","author":"Y Wang","year":"2007","unstructured":"Wang, Y. & microRNA Past and present. Front. Biosci. 12, 2316 (2007).","journal-title":"Front. Biosci."},{"key":"40046_CR73","doi-asserted-by":"publisher","first-page":"122","DOI":"10.3892\/br.2013.192","volume":"2","author":"X Lin","year":"2014","unstructured":"Lin, X. et al. miR-101 inhibits cell proliferation by targeting Rac1 in papillary thyroid carcinoma. Biomedical Rep. 2, 122\u2013126 (2014).","journal-title":"Biomedical Rep."},{"key":"40046_CR74","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1097\/COC.0000000000001106","volume":"47","author":"T Zhang","year":"2024","unstructured":"Zhang, T., Hu, Y., Yang, N., Yu, S. & Pu, X. The microRNA-34 family and its functional role in lung cancer. Am. J. Clin. Oncol. 47, 448\u2013457 (2024).","journal-title":"Am. J. Clin. Oncol."},{"key":"40046_CR75","first-page":"2249","volume":"34","author":"C Thorns","year":"2014","unstructured":"Thorns, C. et al. Global MicroRNA profiling of pancreatic neuroendocrine neoplasias. Anticancer Res. 34, 2249\u20132254 (2014).","journal-title":"Anticancer Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-40046-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-40046-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-40046-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:22:16Z","timestamp":1781634136000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-40046-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,17]]},"references-count":75,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["40046"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-40046-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,17]]},"assertion":[{"value":"26 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Federica Scalorbi, Dr. Marco Maccauro, Dr Massimo Milione, and Dr. Sara Pusceddu received honoraria as consultants and speakers from AAA (Advanced Accelerator Applications) and Novartis Pharmaceuticals Corporation, outside the submitted work. The remaining authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9430"}}